What is the expected value of the obesity drug market?

It is estimated at over $100 billion by 2030.

Which company is a better long-term investment?

It depends on risk tolerance: Johnson & Johnson is more stable, while Eli Lilly offers higher growth with greater risk.

What GLP-1 drugs does Eli Lilly produce?

Eli Lilly produces Mounjaro and Zepbound for diabetes and obesity.

Johnson & Johnson Walks Away From $100B Obesity Market: Better Buy Than Eli Lilly?

Johnson & Johnson is steering clear of the $100 billion obesity drug market, focusing on its diversified portfolio instead. A comparative analysis with Eli Lilly, the market leader.

July 4, 2026

2 min read

Source: Motley Fool

According to a report from Motley Fool, Johnson & Johnson (JNJ) is taking a different approach from rival Eli Lilly (LLY) regarding the lucrative obesity drug market, estimated at over $100 billion. While Eli Lilly focuses on GLP-1 drugs like Mounjaro and Zepbound, Johnson & Johnson is avoiding this space, relying on its diversified product portfolio in pharmaceuticals and medical devices.

Details

Johnson & Johnson does not see the need to enter the GLP-1 market to achieve growth, as it already has a broad portfolio including oncology, immunology, and medical devices. In contrast, Eli Lilly has become a leader in the obesity market thanks to the success of its drugs, driving rapid revenue growth.

Context

The obesity drug market is highly competitive between Eli Lilly and Novo Nordisk, with expectations of growth to over $100 billion by 2030. However, Johnson & Johnson chooses to focus on other areas that may be less volatile.

What It Means for Investors

For investors, Johnson & Johnson's less concentrated strategy may be safer in the long term, given the regulatory and competitive uncertainties in the obesity market. Meanwhile, Eli Lilly offers higher growth potential but with greater risk. The choice depends on the investor's risk tolerance.

Frequently Asked Questions

Because it relies on a diversified portfolio in pharmaceuticals and medical devices and does not see the need to enter the GLP-1 market to achieve growth.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.